Cardioprotective effects of nicorandil on coronary heart disease patients undergoing elective percutaneous coronary intervention

Medical Science Monitor

Volumn 23, Issue , 2017, Pages 2924-2930

  Pang, Zhihua ^a   Zhao, Wei ^b   Yao, Zhuhua ^a  

^a TIANJIN UNION MEDICAL CENTER   (China)

^b Heyuan Community Health Service Centers of Hongqiao District   (China)

Author keywords

Coronary disease; Nicorandil; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CREATINE KINASE MB; LOW MOLECULAR WEIGHT HEPARIN; MALONALDEHYDE; MYELOPEROXIDASE; NICORANDIL; THIOBARBITURIC ACID; TROPONIN I; CARDIOTONIC AGENT; PEROXIDASE;

ADULT; AGED; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY BLOOD FLOW; DIABETES MELLITUS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART PROTECTION; HEART RATE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; COMPLICATION; CORONARY ARTERY DISEASE; DIASTOLE; DRUG EFFECTS; ELECTIVE SURGERY; HEART STROKE VOLUME; NO REFLOW PHENOMENON; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SYSTOLE;

BLOOD PRESSURE; CARDIOTONIC AGENTS; CORONARY DISEASE; CREATINE KINASE, MB FORM; DIASTOLE; ELECTIVE SURGICAL PROCEDURES; FEMALE; HEART RATE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; NICORANDIL; NO-REFLOW PHENOMENON; PERCUTANEOUS CORONARY INTERVENTION; PEROXIDASE; STROKE VOLUME; SYSTOLE; TROPONIN I;

EID: 85021199272     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.902324     Document Type: Article

References (42)

1. Li L, Pan Y, Dai L et al: Association of genetic polymorphisms on vascular endothelial growth factor and its receptor genes with susceptibility to coronary heart disease. Med Sci Monit, 2016; 22: 31–40
2. Gaziano TA, Bitton A, Anand S et al: Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol, 2010; 35: 72–115
3. Mendis S, Lindholm LH, Mancia G et al: World Health Organization (WHO) and International Society of Hypertension (ISH) risk prediction charts: assessment of cardiovascular risk for prevention and control of cardiovascular disease in low and middle-income countries. J Hypertens, 2007; 25: 1578–82
4. Plotek W, Pielok J, Cybulski M, Samborska R: Emotional processes in patients undergoing coronary artery bypass graft surgeries with extracorpo-real circulation in view of selected indicators of the inflammatory condition. Med Sci Monit, 2015; 21: 105–17
5. Kostic J, Djordjevic-Dikic A, Dobric M et al: The effects of nicorandil on microvascular function in patients with ST segment elevation myocardial infarction undergoing primary PCI. Cardiovasc Ultrasound, 2015; 13: 26
6. Klein LW, Kramer BL, Howard E, Lesch M: Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol, 1991; 17: 621–26
7. Vescovo G, Zaninotto M, Casiglia E et al: Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. Am J Cardiol, 1987; 59: 999–1000
8. Jaffe R, Charron T, Puley G et al: Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 2008; 117: 3152–56
9. Zemánek D, Branny M, Martinkovičová L et al: Effect of seven-day ator-vastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study. Int J Cardiol, 2013; 168: 2494–97
10. Li Q, Deng SB, Xia S et al: Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: A clinical study. Med Clin (Barc), 2013; 140: 532–36
11. Kurz DJ, Naegeli B, Bertel O: A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postpro-cedural chest pain and minor myocardial necrosis after elective coronary stenting. Am Heart J, 2000; 139: 35–43
12. Wang FW, Osman A, Otero J et al: Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation, 2003; 107: 2914–19
13. Tcheng JE, Harrington RA, Kottke-Marchant K et al: Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation, 1995; 91: 2151–57
14. Markham A, Plosker GL, Goa KL: Nicorandil. An updated review of its use in ischaemic heart disease with emphasis on its cardioprotective effects. Drugs, 2000; 60: 955–74
15. IONA Study Group: Effect of nicorandil on coronary events in patients with stable angina: The Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet, 2002; 359: 1269–75
16. Somma SD, Liguori V, Petitto M et al: A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther, 1993; 7: 119–23
17. Ono H, Osanai T, Ishizaka H, Hanada H: Nicorandil improves cardiac function and clinical outcome in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: Role of inhibitory effect on reactive oxygen species formation. Am Heart J, 2004; 148: E15
18. Kim JH, Jeong MH, Yun KH et al: Myocardial protective effects of nicorandil during percutaneous coronary intervention in patients with unstable angina. Circ J, 2005; 69: 306–10
19. Yang J, Zhang J, Cui W et al: Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. Anatol J Cardiol, 2015; 15: 125–31
20. Gibson CM, Cannon CP, Daley WL et al: TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation, 1996; 93: 879–88
21. Kawecki D, Morawiec B, Dola J et al: Comparison of first- and second-gen-eration drug-eluting stents in an all-comer population of patients with diabetes mellitus (from Katowice-Zabrze Registry). Med Sci Monit, 2015; 21: 3261–69
22. Ramesh D, Setty HS, Patil V et al: Use of CT angiogram in interventions involving coronary artery anomalies: A case series. Am J Case Rep, 2015; 16: 858–62
23. Vallejo E, Peña-Duque MA, Noroño O et al: [The no-reflow phenomenon: its incidence and clinical characteristics in a series of cases]. Arch Inst Cardiol Mex, 1998; 68(3): 247–52 [in Spanish]
24. Morishima I, Sone T, Okumura K et al: Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol, 2000; 36: 1202–9
25. Brosh D, Assali AR, Mager A et al: Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality. Am J Cardiol, 2007; 99: 442–45
26. Sakai K, Yamagata T, Teragawa H et al: Nicorandil enhances myocardial tolerance to ischemia without progressive collateral recruitment during coronary angioplasty. Circ J, 2002; 66: 317–22
27. Ito H, Taniyama Y, Iwakura K et al: Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction – its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Am Coll Cardiol, 1999; 33: 654–60
28. Ota S, Nishikawa H, Takeuchi M et al: Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). Circ J, 2006; 70: 1099–104
29. Ikeda N, Yasu T, Kubo N et al: Nicorandil versus isosorbide dinitrate as adjunctive treatment to direct balloon angioplasty in acute myocardial infarction. Heart, 2004; 90: 181–85
30. Nameki M, Ishibashi I, Miyazaki Y et al: Comparison between nicorandil and magnesium as an adjunct cardioprotective agent to percutaneous coronary intervention in acute anterior myocardial infarction. Circ J, 2004; 68: 192–97
31. Ueda H, Nakayama Y, Tsumura K et al: Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. Can J Cardiol, 2004; 20: 625–29
32. Isono T, Kamihata H, Sutani Y et al: Nicorandil suppressed myocardial injury after percutaneous coronary intervention. Int J Cardiol, 2008; 123: 123–28
33. Kato T, Kamiyama T, Maruyama Y et al: Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am Heart J, 2001; 141: 940–43
34. Kukovetz WR, Holzmann S, Pöch G: Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol, 1992; 20 Suppl 3: S1–7
35. Akai K, Wang Y, Sato K et al: Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol, 1995; 26: 541–47
36. Hongo M, Takenaka H, Uchikawa S et al: Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol, 1995; 75: 246–50
37. Ito N, Nanto S, Doi Y et al: Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study. Cardiovasc Drug Ther, 2013; 27: 279–87
38. Hammadah M, Mheid IA, Wilmot K et al: High sensitivity cardiac troponin i is associated with mental and conventional stress induced myocardial ischemia. J Am Coll Cardiol, 2016; 67: 2346
39. Gollop ND, Dhullipala A, Nagrath N, Myint PK: Is periprocedural CK-MB a better indicator of prognosis after emergency and elective percutaneous coronary intervention compared with post-procedural cardiac troponins? Interact Cardiovasc Thorac Surg, 2013; 17: 867–71
40. Ahmed N, Carberry J, Teng V et al: Risk assessment in patients with an acute ST-elevation myocardial infarction. J Comp Eff Res, 2016; 5(6): 581–93
41. Meng G, Wang J, Xiao Y et al: GYY4137 protects against myocardial ischemia and reperfusion injury by attenuating oxidative stress and apoptosis in rats. J Biomed Res, 2015; 29: 203–13
42. Richards AM, Nicholls MG, Espiner EA et al: B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation, 2003; 107: 2786–92